Compare RDW & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | FLGT |
|---|---|---|
| Founded | 2020 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 867.4M |
| IPO Year | N/A | 2016 |
| Metric | RDW | FLGT |
|---|---|---|
| Price | $10.21 | $27.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $12.67 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 23.0M | 212.7K |
| Earning Date | 03-09-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $296,147,000.00 | ★ $315,549,000.00 |
| Revenue This Year | $11.62 | $16.84 |
| Revenue Next Year | $41.41 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.61 |
| 52 Week Low | $4.87 | $14.57 |
| 52 Week High | $26.66 | $31.04 |
| Indicator | RDW | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 53.46 |
| Support Level | $9.67 | $27.39 |
| Resistance Level | $12.46 | $28.95 |
| Average True Range (ATR) | 1.24 | 0.79 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 55.36 | 72.16 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.